BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology company with a market capitalization of ...

Aclarion (ACON) has secured full funding for its pivotal CLARITY trial which is designed to demonstrate Nociscan’s clinical and economic value ...

Aclarion, Inc. has announced that Northwestern Medicine will serve as the initial site for its pivotal clinical trial, CLARITY, designed to assess the effectiveness and economic value of Nociscan ...

Northwestern Medicine is a global leader in clinical trial research, including spineCLARITY is a randomized study designed to demonstrate ...

Aclarion stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its ...

The trial aims to validate Nociscan’s ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data ...

“We are pleased to participate in Aclarion’s CLARITY trial, a groundbreaking randomized controlled trial examining Nociscan’s impact on discogenic low back pain surgical outcomes. Low back ...

Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE ...

CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in ...